Vertex Pharmaceuticals announced on July 7 its acquisition of Crinetics Pharmaceuticals for $10 billion, marking the company's entry into the specialty endocrinology sector. The deal, which is expected to close in the third quarter, will see Vertex pay $85 per share for Crinetics, representing a premium of approximately 102% over Crinetics' closing price of $42.03 per share.
Crinetics brings to Vertex an FDA-approved acromegaly pill called Palsonify and a late-stage therapy candidate for congenital adrenal hyperplasia (CAH) named atumelnant. Palsonify was approved in September 2025 and generated $5.4 million in revenue by the end of that year, with first-quarter revenue rising to $10.3 million this year.
Stifel analysts said specialty endocrinology markets “represent emerging white space blockbuster opportunities.” They also said, “Unless atumelnant encounters a significant safety issue, the deal will over time add another interesting growth angle to VRTX.”
BMO Capital Markets described the transaction as the largest in Vertex’s history and one of this year's highest-value takeovers. BMO said it sees the deal as strengthening Vertex's leadership position in rare diseases and broadening its offerings beyond cystic fibrosis treatments: “We are positive on the deal for Vertex as the company works to broaden its offering in rare disease and leverage its experience commercializing specialty products.”
Vertex expects Palsonify and atumelnant together could deliver more than $5 billion in combined annual revenue at peak sales. The company is also awaiting potential approval later this year for povetacicept, a fusion protein targeting IgA nephropathy.
